Browse studies
Find your next paid study
3 recruiting studies matching your filters
Phase 2
A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab
Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the lab…
Metastatic Colorectal CancerMetastatic Pancreatic CancerMetastatic Ovarian Cancer+2 more
Estimated
~$10 – $5,625
National Cancer Institute (NCI)NCT01174121
Phase 1
A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Antitumor Activity of ARR-002 in Adults With Locally Advanced or Metastatic Ovarian or Endometrial Cancer.
This is a Phase 1 study to assess safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ARR-002 in advanced or metastatic ovarian o…
Ovarian CancerEndometrial CancerPlatinum-resistant Ovarian Cancer (PROC)+2 more
Estimated
~$10 – $8,750
ArriVent BioPharma, Inc.NCT07755436
Phase 2
A Phase 2 Randomized Trial of Sacituzumab Tirumotecan (MK2870) Alone and in Combination With Pembrolizumab in Ovarian Clear Cell Carcinoma Previously Exposed to Immunotherapy
This is a phase II randomized study of Sacituzumab tirumotecan, an intravenous antibody-drug conjugate (ADC) that targets Trop-1, administered alone or in comb…
Ovarian Clear Cell CarcinomaMetastatic Ovarian CancerRecurrent Ovarian Clear Cell Adenocarcinoma
Estimated
~$10 – $6,250
Tufts Medical CenterNCT07718854